[Therapy of peripheral arterial circulation disorders using 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine (BL 191)].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000175:diagnosis; D005069:Evaluation Studies as Topic; D005260:Female; D005734:Gangrene / Q000188:drug therapy; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014717:Vertigo / Q000139:chemically induced; D014970:Xanthines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014970:Xanthines
Behandlung peripherer arterieller Durchbluntungsstörungen mit 3,7-Dimethyl-1-(5-oxo-hexyl)-xanthin (BL-191.